Tipifarnib in Treating Patients With Metastatic Malignant Melanoma
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This phase II trial is studying how well tipifarnib works in treating patients with
metastatic malignant melanoma. Tipifarnib may stop the growth of tumor cells by blocking the
enzymes necessary for tumor cell growth.